Recombinant Human sRANK Ligand
(Receptor activator of nuclear factor kappa-B ligand); Tumor necrosis factor ligand superfamily member 11 (TNFSF11), Osteoprotegerin ligand (OPGL), TNF-related activatio
- Known as:
- Recombinant Human sRANK Ligand
(Receptor activator nuclear factor kappa-B ligand); Tumor necrosis factor ligand supergroup member 11 (TNFSF11), Osteoprotegerin ligand (OPGL), TNF-related activatio
- Catalog number:
- RF0038-50
- Product Quantity:
- 50ug
- Category:
- -
- Supplier:
- Agren
- Gene target:
- Recombinant Human sRANK Ligand
(Receptor activator nuclear factor kappa- ligand); Tumor necrosis ligand superfamily member 11 (TNFSF11) Osteoprotegerin (OPGL) TNF-related activatio
Related genes to: Recombinant Human sRANK Ligand
(Receptor activator of nuclear factor kappa-B ligand); Tumor necrosis factor ligand superfamily member 11 (TNFSF11), Osteoprotegerin ligand (OPGL), TNF-related activatio
- Gene:
- CDC42BPG NIH gene
- Name:
- CDC42 binding protein kinase gamma
- Previous symbol:
- -
- Synonyms:
- HSMDPKIN, MRCKgamma, DMPK2, kappa-200
- Chromosome:
- 11q13.1
- Locus Type:
- gene with protein product
- Date approved:
- 2004-11-15
- Date modifiied:
- 2016-11-11
- Gene:
- NFKB1 NIH gene
- Name:
- nuclear factor kappa B subunit 1
- Previous symbol:
- -
- Synonyms:
- KBF1, p105, NFKB-p50, p50, NF-kappaB, NFkappaB, NF-kB1
- Chromosome:
- 4q24
- Locus Type:
- gene with protein product
- Date approved:
- 1991-11-14
- Date modifiied:
- 2019-04-23
- Gene:
- NFKBIA NIH gene
- Name:
- NFKB inhibitor alpha
- Previous symbol:
- NFKBI
- Synonyms:
- IKBA, MAD-3, IkappaBalpha
- Chromosome:
- 14q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-02-13
- Date modifiied:
- 2019-04-23
- Gene:
- NFKBID NIH gene
- Name:
- NFKB inhibitor delta
- Previous symbol:
- -
- Synonyms:
- TA-NFKBH, IkappaBNS, IkBNS
- Chromosome:
- 19q13.12
- Locus Type:
- gene with protein product
- Date approved:
- 2008-04-10
- Date modifiied:
- 2019-02-25
- Gene:
- NKIRAS1 NIH gene
- Name:
- NFKB inhibitor interacting Ras like 1
- Previous symbol:
- -
- Synonyms:
- KBRAS1, kappaB-Ras1
- Chromosome:
- 3p24.2
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-31
- Date modifiied:
- 2016-10-05
Related products to: Recombinant Human sRANK Ligand
(Receptor activator of nuclear factor kappa-B ligand); Tumor necrosis factor ligand superfamily member 11 (TNFSF11), Osteoprotegerin ligand (OPGL), TNF-related activatio
Related articles to: Recombinant Human sRANK Ligand
(Receptor activator of nuclear factor kappa-B ligand); Tumor necrosis factor ligand superfamily member 11 (TNFSF11), Osteoprotegerin ligand (OPGL), TNF-related activatio
- Phenylketonuria (PKU) is the most common inherited disorder of amino acid metabolism, characterized by high levels of phenylalanine (Phe) in the blood and brain, leading to cognitive impairment without treatment. Nevertheless, Phe-mediated brain dysfunction is not fully understood. The objective of this study was to address gene expression alterations due to excessive Phe exposure in the human neuronal model and provide molecular advances in PKU pathophysiology. Hence, we performed NT2/D1 differentiation in culture, and, for the first time, we used Phe-treated NT2-derived neurons (NT2/N) as a novel model for Phe-mediated neuronal impairment. NT2/N were treated with 1.25 mM, 2.5 mM, 5 mM, 10 mM, and 30 mM Phe and subjected to whole-mRNA short-read sequencing. Differentially expressed genes (DEGs) were analyzed and enrichment analysis was performed. Under three different Phe concentrations (2.5 mM, 5 mM, and 10 mM), DEGs pointed to the , , , , , and genes, placing them in the context of PKU for the first time. Enriched processes included dendrite and axon impairment, synaptic transmission, and membrane assembly. In contrast to these groups, the 30 mM Phe treatment group clearly represented the neurotoxicity of Phe, exhibiting enrichment in apoptotic pathways. In conclusion, we established NT2/N as a novel model for Phe-mediated neuronal dysfunction and outlined the Phe-induced gene expression changes resulting in neurite impairment and altered synaptic connectivity. - Source: PubMed
Publication date: 2024/09/18
Stankovic SaraLazic AndrijanaParezanovic MarinaStevanovic MilenaPavlovic SonjaStojiljkovic MajaKlaassen Kristel - The recent guidelines suggest the use of genome-wide analyses, such as whole exome sequencing (WES), at the beginning of the diagnostic approach for cases with suspected genetic conditions. However, in many realities it still provides for the execution of a multi-step pathway, thus requiring several genetic tests to end the so-called 'diagnostic odyssey'. - Source: PubMed
Publication date: 2023/12/02
Rosina EricaPezzani LidiaApuril ErikaPezzoli LauraMarchetti DanielaBellini MatteoLucca CamillaMeossi CamillaMassimello MartaMariani MilenaScatigno AgneseCattaneo ElisaColombo LorenzoMaitz SilviaCereda AnnaMilani DonatellaSpaccini LuiginaBedeschi Maria FrancescaSelicorni AngeloIascone Maria - Chronic kidney disease (CKD) is an important social health problem characterized by a decrease in the kidney glomerular filtration rate (GFR). In this study, we analyzed genome-wide association studies for kidney disease-related traits using data from a Korean adult health screening cohort comprising 7,064 participants. Kidney disease-related traits analyzed include blood urea nitrogen (BUN), serum creatinine, estimated GFR, and uric acid levels. We detected two genetic loci (SLC14A2 and an intergenic region) and 8 single nucleotide polymorphisms (SNPs) associated with BUN, 3 genetic loci (BCAS3, C17orf82, ALDH2) and 6 SNPs associated with serum creatinine, 3 genetic loci (BCAS3, C17orf82/TBX2, LRP2) and 7 SNPs associated with GFR, and 14 genetic loci (3 in ABCG2/PKD2, 2 in SLC2A9, 3 in intergenic regions on chromosome 4; OTUB1, NRXN2/SLC22A12, CDC42BPG, RPS6KA4, SLC22A9, and MAP4K2 on chromosome 11) and 84 SNPs associated with uric acid levels. By comparing significant genetic loci associated with serum creatinine levels and GFR, rs9895661 in BCAS3 and rs757608 in C17orf82 were simultaneously associated with both traits. The SNPs rs11710227 in intergenic regions on chromosome 3 showing significant association with BUN is newly discovered. Genetic variations of multiple gene loci are associated with kidney disease-related traits, and differences in associations between kidney disease-related traits and genetic variation are dependent on the population. The meanings of the mutations identified in this study will need to be reaffirmed in other population groups in the future. - Source: PubMed
Publication date: 2018/03/20
Lee JeonghwanLee YoungPark BoramWon SunghoHan Jin SukHeo Nam Ju - Chronic kidney disease and hyperuricemia are serious global health problems. Recent genome-wide association studies have identified various genetic variants related to these disorders. However, most studies have been conducted in a cross-sectional manner. To identify novel susceptibility loci for chronic kidney disease or hyperuricemia, we performed longitudinal exome-wide association studies (EWASs), using ~ 244,000 genetic variants and clinical data of Japanese individuals who had undergone annual health checkups for several years. After establishing quality controls, the association of renal function-related traits in 5648 subjects (excluding patients with dialysis and population outliers) with 24,579 single nucleotide variants (SNVs) for three genetic models (P < 3.39 × 10) was tested using generalized estimating equation models. The longitudinal EWASs revealed novel relations of five SNVs to renal function-related traits. Cross-sectional data for renal function-related traits in 7699 Japanese subjects were examined in a replication study. Among the five SNVs, rs55975541 in CDC42BPG was significantly (P < 4.90 × 10) related to the serum concentration of uric acid in the replication cohort. We also examined the SNVs detected in our longitudinal EWASs with the information on P values in GKDGEN meta-analysis data. Four SNVs in SLC15A2 were significantly associated with the estimated glomerular filtration rate in European ancestry populations, although these SNVs were related to the serum concentration of uric acid with borderline significance in our longitudinal EWASs. Our findings indicate that CDC42BPG may be a novel susceptibility locus for hyperuricemia. - Source: PubMed
Publication date: 2017/11/09
Yasukochi YoshikiSakuma JunTakeuchi IchiroKato KimihikoOguri MitsutoshiFujimaki TetsuoHoribe HidekiYamada Yoshiji - Myotonic dystrophy kinase-related Cdc42 binding kinases (MRCKs) are family members most related to the myotonic dystrophy kinase (DMPK), RhoA-binding kinase (ROK), and citron kinase. Two highly conserved members, MRCKalpha and -beta, have been previously identified and characterized. We now describe a novel isoform, MRCKgamma, which is functionally and structurally related to members of this kinase family. We show these kinases to have marked similarities in their genomic organization, substrate phosphorylation, and catalytic autoinhibition. Unlike MRCKalpha and -beta, which are expressed ubiquitously, MRCKgamma mRNA was only expressed in heart and skeletal muscle. In cultured cells, MRCKgamma showed differential expression with high levels of expression only in certain cell lines. DNA analysis showed that lack of expression is correlated with promoter DNA methylation. We have mapped the methylation sites in the MRCKgamma promoter. Significantly, agents that suppressed DNA methylation caused increases in the expression of the kinase in low-expressing cells, further supporting the notion that promoter DNA methylation plays an important role in the expression of MRCKgamma. Analysis of the MRCKgamma promoter has also revealed two proximal Sp1 sites that are essential for transcriptional activity. We conclude that both promoter DNA methylation and Sp1 binding are important regulators for MRCKgamma expression. - Source: PubMed
Publication date: 2004/06/11
Ng YvonneTan IvanLim LouisLeung Thomas